We are live on ! Find out more
FCMI

Foresite Capital Management III Portfolio holdings

AUM $37.9M
1-Year Est. Return 6.87%
This Fund
S&P 500
This Quarter Est. Return
-22.83%
1 Year Est. Return
-6.87%
3 Year Est. Return
+444.07%
5 Year Est. Return
+547.28%
10 Year Est. Return
AUM
$32.8M
AUM Growth
-$6.68M
Cap. Flow
+$4.1M
Cap. Flow %
12.48%
Top 10 Hldgs %
100%
Holding
4
New
Increased
1
Reduced
Closed

Top Buys

Rank Stock Value
1
NTRA icon
Natera
NTRA
+$4.1M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ASND icon
1
Ascendis Pharma A/S
ASND
$16.3B
$15.7M 47.81%
133,691
NTRA icon
2
Natera
NTRA
$36.7B
$6.47M 19.73%
159,160
+68,160
+75% +$4.1M
VRNA
3
DELISTED
Verona Pharma
VRNA
$5.54M 16.89%
1,111,112
CBAY
4
DELISTED
Cymabay Therapeutics
CBAY
$5.11M 15.56%
1,641,804

Similar funds

Foresite Capital Management III's Q1 2022 Portfolio in Review

As of Q1 2022, Foresite Capital Management III held 4 positions worth $32.8M, down 17% from $39.5M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Foresite Capital Management III deployed $4.1M of net new capital in Q1 2022, adding to 1 existing holding.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Foresite Capital Management III added most to Natera in Q1 2022, an estimated $4.1M increase.
  • Foresite Capital Management III's ten largest holdings make up 100% of its $32.8M portfolio in Q1 2022.
  • Foresite Capital Management III opened 0 new positions and closed 0 in Q1 2022.
  • Foresite Capital Management III's portfolio value fell 17% quarter-over-quarter to $32.8M.

Based on Foresite Capital Management III's 13F filing for Q1 2022, filed 13 May 2022.